Ingevity Corporation (NYSE:NGVT) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analysts maintain a “Hold” consensus on Ingevity, with three hold ratings and two buy ratings. The average 12-month price target is $80.00, above the reported share price of $71.33.
• Ingevity’s latest quarterly results exceeded expectations, with EPS of $1.74 versus the $1.33 consensus estimate and revenue of $314.1 million. The stock was trading down 3.6%, with a market capitalization of approximately $2.45 billion.
• Insiders sold shares worth roughly $1.38 million over the past 90 days, while institutional investors own 91.59% of the company’s stock.

Ingevity Corporation (NYSE:NGVT - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five analysts that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $80.00.

Several equities research analysts have commented on NGVT shares. Weiss Ratings raised shares of Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, July 31st. Wall Street Zen lowered shares of Ingevity from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 1st.

Ingevity Trading Down 3.6%

NYSE:NGVT opened at $71.33 on Thursday. Ingevity has a 12 month low of $45.85 and a 12 month high of $79.29. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52. The firm's 50 day moving average is $73.91 and its 200 day moving average is $71.82. The stock has a market capitalization of $2.45 billion, a PE ratio of 48.53 and a beta of 1.16.

Ingevity (NYSE:NGVT - Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.33 by $0.41. The business had revenue of $314.10 million during the quarter, compared to the consensus estimate of $312.20 million. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Sell-side analysts expect that Ingevity will post 5.4 earnings per share for the current year.

Insider Buying and Selling at Ingevity

In other Ingevity news, SVP Terrance M. Dyer sold 496 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total transaction of $33,971.04. Following the sale, the senior vice president owned 7,202 shares in the company, valued at $493,264.98. This represents a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Ryan C. Fisher sold 2,709 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $73.72, for a total value of $199,707.48. Following the completion of the transaction, the senior vice president directly owned 15,722 shares of the company's stock, valued at $1,159,025.84. The trade was a 14.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,297 shares of company stock valued at $1,381,452 in the last 90 days. 0.88% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC purchased a new stake in shares of Ingevity in the fourth quarter worth about $27,000. Frazier Financial Advisors LLC purchased a new position in Ingevity during the second quarter valued at approximately $37,000. Meeder Asset Management Inc. bought a new stake in Ingevity during the 4th quarter worth approximately $33,000. Kestra Advisory Services LLC purchased a new stake in Ingevity in the 4th quarter worth approximately $47,000. Finally, Geneos Wealth Management Inc. lifted its stake in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company's stock worth $36,000 after purchasing an additional 387 shares in the last quarter. Hedge funds and other institutional investors own 91.59% of the company's stock.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source